Using a special peptide to deliver cancer drugs directly to brain tumors
Targeting platinum(IV) prodrug to GBM tumors using a brevican-binding peptide
This study is working on a new way to help people with glioblastoma by creating a special delivery method for cancer drugs that can get past the protective barrier in the brain, so they can better target and treat the tumor.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Brigham and Women's Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-10917200 on NIH RePORTER |
What this research studies
This research focuses on improving treatment for glioblastoma (GBM), a challenging brain tumor, by developing a new method to deliver cancer drugs across the blood-brain barrier (BBB). The team is collaborating to create a peptide that can specifically target GBM cells and facilitate the delivery of a platinum-based drug that typically cannot penetrate the BBB. The project involves testing the effectiveness of this peptide-drug combination in laboratory settings to ensure it can reach and treat the tumor effectively.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with glioblastoma who are 21 years or older.
Not a fit: Patients with other types of brain tumors or those under 21 years old may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with glioblastoma by ensuring that potent anti-cancer drugs can reach the tumor cells.
How similar studies have performed: Other research has shown promise in using targeted delivery methods for cancer therapies, suggesting that this approach could be effective.
Where this research is happening
Boston, United States
- Brigham and Women's Hospital — Boston, United States (Active)
Researchers
- Principal investigator: Cho, Choi-Fong — Brigham and Women's Hospital
- Study coordinator: Cho, Choi-Fong
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.